Key Drivers
- Cash Cushion
- Zero Revenue
- Equity Erosion
AIAI Summary
FBRX has moved from a cash-burn biotech to an early proof-of-concept story in vitiligo, but after the sharp rerating the investment now hinges on whether FB102's efficacy signal holds up in larger trials—if it does, the platform and multi-indication upside are real, but if it doesn't, the premium could unwind fast.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Zero Revenue
- •Equity Erosion
FBRX has solid short-term liquidity and no debt, but persistent zero revenue, heavy cash burn, and shrinking equity make the business look operationally weak despite its cash cushion.
Price Behavior
Key Price Behavior Insights:
- •Base Breakout
- •Sharp Extension
- •Mid-$30 Support
FBRX has surged sharply over the last month and just broke out above a long base, but the move looks stretched and volatile, so holding above the mid-$30s is key.
Explosive move from $16.82 to $43.92 with sharp breakout spikes after a long $18-$22 base
Sentiment & News
Key News Insights:
- •Vitiligo efficacy
- •Durable response
- •Favorable safety
Forte Biosciences rallied sharply after early phase 1b FB102 data in vitiligo showed statistically significant, durable repigmentation with a favorable safety profile, boosting confidence in the broader pipeline.
The readout is a strong bullish catalyst that could keep FBRX volatile higher as investors reassess FB102's development upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings